Osteopore (ASX:OSX) launched a clinical trial with Princess Alexandra Hospital for the reconstruction of jawbones in at least 10 adult patients, with the single-arm feasibility trial will be conducted in Australia, according to a Wednesday ASX filing.
It plans to determine the safety and tolerability of polycaprolactone-tricalcium phosphate scaffolds with a vascularized corticoperiosteal tissue transfer. The technique, applied with the polycaprolactone-tricalcium phosphate scaffolds, was previously successfully employed in previous cranial and long-bone reconstruction trials.
Patient recruitment for the maxillomandibular reconstruction trial is expected by 2028, and patient follow-up is expected to be 36 months post-surgery.
The Human Research and Ethics Committee at Metro South Health provided clearance, while the firm expects clearance from the Research Governance Office.
Its shares jumped 7% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.